ArticleMolecular biotechnology2026
Evaluation of Suitability, Efficacy, and Safety of Zinc Hydroxide Adjuvant System Adsorbed on Tetanus Toxoid Vaccine.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the current study, zinc hydroxide gel was prepared as an adjuvant system for adsorption of tetanus toxoid antigen. The vaccine's efficacy was established by estimating different immunological markers (IgG, IL-1α, IL-1β, IL-6) against tetanus antigen in mice (n = 48, Swiss albino Balb/C strain) at suitable intervals to develop protective antibody titers. The safety of the test formulation was confirmed by specific toxicity studies in guinea pigs (n = 7, Dunkin Hartley strain). The efficacy of the tetanus toxoid vaccine such prepared was increased by incorporating zinc that activated both humoral and cell-mediated immune responses. The test formulation demonstrated improved potency (113.8 IU/SHD) compared with the control formulation (106.4 IU/SHD). Toxicity studies were conducted on mice and guinea pigs to ensure safety. The test formulation (containing zinc hydroxide as adjuvant) showed a majority of small-sized particles (2.0-5.0 µm) compared to the control, with few larger particles (> 100 µm). Immunological markers were elevated in the test formulation compared to the control, indicating a better immune response. The low zinc concentration in the test formulation could reduce potential toxicity risks.
Indexed as
Identifiers
41196532What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.